219 completed. 219 Phase 3, 26 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 219 | Completed 219 |
| Phase 2 | 26 | Completed 26 |
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients Experimental: Venetoclax in combination with Decitabine (+-sorafenib), Active Comparator: Standard dose of Venetoclax + Azacitidine - Elderly AML Patients, Unfit, New-diagnosis AML | Phase 3 | Completed | The Second Affiliated Hospital of Kunming Medical University | 154 | 2023-11-01 | 2026-09-09 |
| Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML Azacitidine Combined With Venetoclax and ATRA group - Acute Myeloid Leukemia | Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 60 | 2022-10-31 | 2026-06-18 |
| Asciminib Treatment Optimization in ≥ 3rd Line CML-CP ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 199 | 2021-10-13 | 2026-03-18 |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation ABL001 - Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Completed | Novartis Pharmaceuticals | 56 | 2021-05-25 | 2025-10-16 |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML Glasdegib, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Completed | Pfizer | 14 | 2021-05-17 | 2023-12-18 |
| A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) Venetoclax, Cytarabine - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | AbbVie | 14 | 2020-10-05 | 2022-05-05 |
| A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | AbbVie | 112 | 2020-03-26 | 2026-04-08 |
| A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Venetoclax, Azacitidine, Decitabine - Acute Myeloid Leukemia (AML), Cancer | Phase 3 | Completed | AbbVie | 60 | 2019-08-15 | 2023-03-20 |
| TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate - Acute Leukemia, Chronic Myelogenous Leukemia (CML) | Phase 3 | Completed | Medical College of Wisconsin | 431 | 2019-06-25 | 2024-04-04 |
| Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT Oral azacitidine, Matched placebo - Acute Myeloid Leukemia, Myelodysplasia | Phase 3 | Completed | University of Birmingham | 326 | 2019-06-14 | 2026-08-14 |
| A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) Midostaurin, Placebo, Chemotherapy - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | Novartis Pharmaceuticals | 511 | 2018-07-20 | 2023-08-21 |
| Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients Levofloxacin - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 3 | Completed | Centre Henri Becquerel | 60 | 2018-07-18 | 2026-01-02 |
| A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia glasdegib, daunorubicin + cytarabine, azacitidine - Leukemia, Myeloid, Acute | Phase 3 | Completed | Pfizer | 730 | 2018-04-20 | 2023-04-21 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML ASTX727, Dacogen - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 3 | Completed | Astex Pharmaceuticals, Inc. | 227 | 2018-02-15 | 2024-08-27 |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only - Acute Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 301 | 2018-02-13 | 2024-02-29 |
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Azacitidine, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 76 | 2018-02-02 | 2025-01-16 |
| Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients Nalbuphine, Morphine - Acute Myeloid Leukemia, Stem Cell Leukemia | Phase 3 | Completed | Children's Cancer Hospital Egypt 57357 | 80 | 2018-02-01 | 2021-08-02 |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Azacitidine, Pevonedistat - Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic | Phase 3 | Completed | Takeda | 454 | 2017-11-28 | 2025-10-29 |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Asciminib, Bosutinib - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 233 | 2017-10-26 | 2026-08-18 |
Showing 20 of 219. Sign in to see all of them.
Leukemia, Myeloid, Acute (152) · Leukemia (68) · Myelodysplastic Syndromes (53) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (51) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (49) · Leukemia, Myeloid, Chronic-Phase (35) · Leukemia, Myelomonocytic, Chronic (30) · Lymphoma, Non-Hodgkin (30) · Hodgkin Disease (28) · Leukemia, Lymphocytic, Chronic, B-Cell (26) · Leukemia, Myeloid, Accelerated Phase (26) · Lymphoma (25) · Burkitt Lymphoma (24) · Congenital Abnormalities (24) · Lymphoma, Mantle-Cell (24)
Hemic and Lymphatic Diseases (219) · Neoplasms by Histologic Type (218) · Hematologic Diseases (215) · Neoplasms (207) · Leukemia (151) · Bone Marrow Diseases (122) · Pathological Conditions, Signs and Symptoms (102) · Pathologic Processes (100) · Disease Attributes (98) · Chronic Disease (96) · Myeloproliferative Disorders (78) · Immune System Diseases (63) · Immunoproliferative Disorders (56) · Lymphatic Diseases (56)
Cytarabine (63) · Daunorubicin (34) · Etoposide (23) · Cyclophosphamide (22) · Imatinib Mesylate (20) · Idarubicin (18) · Methotrexate (18) · Azacitidine (16) · Busulfan (15) · Mitoxantrone (14) · nilotinib (14) · Gemtuzumab (13) · Peripheral Blood Stem Cell Transplantation (12) · fludarabine (12) · Filgrastim (11)
Novartis Pharmaceuticals (15) · Fred Hutchinson Cancer Center (8) · National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (7) · Children's Oncology Group (6) · European Organisation for Research and Treatment of Cancer - EORTC (6) · University of Ulm (6) · Astex Pharmaceuticals, Inc. (5) · St. Jude Children's Research Hospital (5) · AbbVie (4) · Eastern Cooperative Oncology Group (4) · Medical College of Wisconsin (4) · Memorial Sloan Kettering Cancer Center (4) · Pfizer (4) · Technische Universität Dresden (4)
United States (120) · Germany (71) · France (63) · Italy (54) · Canada (49) · Spain (46) · United Kingdom (42) · Australia (35) · Belgium (35) · Czechia (33) · Poland (31) · South Korea (29) · Austria (27) · Hungary (25) · Israel (24)
Mary Horowitz, MD, MS (3) · Alan K. Burnett, MD, FRCP (2) · Alan S. Gamis, MD, MPH (2) · Brenda Sandmaier (2) · Depei Wu, M.D., Ph.D. (2) · Qifa Liu (2) · Richard F Schlenk, Dr. (2)
PMID 37267439, PMID 31375516, PMID 36184192, PMID 36815378, PMID 37341189, PMID 38295280, PMID 42085603, PMID 19602710, PMID 20625116, PMID 21343560, PMID 22649106, PMID 22965967, PMID 23620574, PMID 24816240, PMID 28273028, PMID 29859851, PMID 30337300, PMID 32499241, PMID 34596937, PMID 35235189, PMID 36064577, PMID 37185873, PMID 37553873, PMID 40294366, PMID 40973764, PMID 42668697, PMID 10438706, PMID 12637609, PMID 15459300, PMID 15761020, PMID 16136166, PMID 16333838, PMID 16484584, PMID 16932345, PMID 16939487, PMID 16960978, PMID 16996130, PMID 17116939, PMID 17151364, PMID 17251531, PMID 17252021, PMID 17315155, PMID 17339189, PMID 17397698, PMID 17715389, PMID 18256322, PMID 19059939, PMID 19117345, PMID 19264678, PMID 19291085
2015 (5), 2016 (4), 2017 (4), U10CA021115 (4), U10CA032102 (4), U10CA098543 (4), U10CA031946 (3), 2008 (2), 2014 (2), P01CA018029 (2), P01CA078902 (2), P30CA015704 (2), P30CA068485 (2), U01HL069294 (2), U10CA095861 (2)